XML 25 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Exit and Realignment Costs
3 Months Ended
Mar. 31, 2024
Restructuring and Related Activities [Abstract]  
Exit and Realignment Costs

Note 4—Exit and Realignment Costs

We periodically incur exit and realignment and other charges associated with optimizing our operations which includes the consolidation of certain facilities, IT strategic initiatives and other strategic actions. These charges also include costs associated with our Operating Model Realignment Program, which include professional fees, severance and other costs to streamline functions and processes.

Exit and realignment charges, net were $27.4 million and $15.7 million for the three months ended March 31, 2024 and 2023. These amounts are excluded from our segments’ operating income.

During the three months ended March 31, 2024, exit and realignment charges, net included a gain of $7.4 million associated with the sale of our corporate headquarters and $34.7 million in charges under our Operating Model Realignment Program and IT strategic initiatives. We expect to incur material future costs relating to our Operating Model Realignment Program and IT strategic initiatives, which we are not able to reasonably estimate.

The following table summarizes the activity related to exit and realignment cost accruals, which are classified as other current liabilities in our consolidated balance sheets, through March 31, 2024 and 2023:

    

Total

Accrued exit and realignment costs, December 31, 2023

$

20,047

Provision for exit and realignment activities:

 

  

Severance

 

184

Professional fees

 

25,625

Other

 

2,493

Cash payments

 

(11,728)

Accrued exit and realignment costs, March 31, 2024

$

36,621

Accrued exit and realignment costs, December 31, 2022

$

969

Provision for exit and realignment activities:

 

  

Severance

 

4,127

Professional fees

9,012

Other

 

2,535

Cash payments

 

(5,546)

Accrued exit and realignment costs, March 31, 2023

$

11,097

In addition to the exit and realignment accruals in the preceding table and the $7.4 million gain associated with the sale of our corporate headquarters, we also incurred $6.5 million of costs that were expensed as incurred for the three months ended March 31, 2024, which primarily related to accelerated depreciation of certain assets held in our Products & Healthcare Services segment.